704 related articles for article (PubMed ID: 11422732)
21. Peroxisome proliferator activated receptors and obesity.
Kersten S
Eur J Pharmacol; 2002 Apr; 440(2-3):223-34. PubMed ID: 12007538
[TBL] [Abstract][Full Text] [Related]
22. Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.
Aleshin S; Strokin M; Sergeeva M; Reiser G
Neurochem Int; 2013 Oct; 63(4):322-30. PubMed ID: 23811400
[TBL] [Abstract][Full Text] [Related]
23. Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro.
Downie MM; Sanders DA; Maier LM; Stock DM; Kealey T
Br J Dermatol; 2004 Oct; 151(4):766-75. PubMed ID: 15491415
[TBL] [Abstract][Full Text] [Related]
24. Peroxisome proliferator-activated receptors in inflammation control.
Delerive P; Fruchart JC; Staels B
J Endocrinol; 2001 Jun; 169(3):453-9. PubMed ID: 11375115
[TBL] [Abstract][Full Text] [Related]
25. Regulation of lipid and lipoprotein metabolism by PPAR activators.
Gervois P; Torra IP; Fruchart JC; Staels B
Clin Chem Lab Med; 2000 Jan; 38(1):3-11. PubMed ID: 10774955
[TBL] [Abstract][Full Text] [Related]
26. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
Alemán G; Torres N; Tovar AR
Rev Invest Clin; 2004; 56(3):351-67. PubMed ID: 15612519
[TBL] [Abstract][Full Text] [Related]
27. The mechanisms of action of PPARs.
Berger J; Moller DE
Annu Rev Med; 2002; 53():409-35. PubMed ID: 11818483
[TBL] [Abstract][Full Text] [Related]
28. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
Leisewitz AV; Urrutia CR; Martinez GR; Loyola G; Bronfman M
J Cell Physiol; 2008 Nov; 217(2):367-76. PubMed ID: 18543250
[TBL] [Abstract][Full Text] [Related]
29. Expression of peroxisome proliferator-activated receptors in zebrafish (Danio rerio).
Ibabe A; Grabenbauer M; Baumgart E; Fahimi HD; Cajaraville MP
Histochem Cell Biol; 2002 Sep; 118(3):231-9. PubMed ID: 12271359
[TBL] [Abstract][Full Text] [Related]
30. Peroxisome proliferator-activated receptors and inflammation.
Moraes LA; Piqueras L; Bishop-Bailey D
Pharmacol Ther; 2006 Jun; 110(3):371-85. PubMed ID: 16168490
[TBL] [Abstract][Full Text] [Related]
31. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis.
Barbier O; Torra IP; Duguay Y; Blanquart C; Fruchart JC; Glineur C; Staels B
Arterioscler Thromb Vasc Biol; 2002 May; 22(5):717-26. PubMed ID: 12006382
[TBL] [Abstract][Full Text] [Related]
32. The role of peroxisome proliferator-activated receptors in healthy and diseased eyes.
Escandon P; Vasini B; Whelchel AE; Nicholas SE; Matlock HG; Ma JX; Karamichos D
Exp Eye Res; 2021 Jul; 208():108617. PubMed ID: 34010603
[TBL] [Abstract][Full Text] [Related]
33. Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels.
Yessoufou A; Wahli W
Swiss Med Wkly; 2010; 140():w13071. PubMed ID: 20842602
[TBL] [Abstract][Full Text] [Related]
34. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions.
Wagner KD; Wagner N
Pharmacol Ther; 2010 Mar; 125(3):423-35. PubMed ID: 20026355
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b.
Shipley JM; Waxman DJ
Toxicol Appl Pharmacol; 2004 Sep; 199(3):275-84. PubMed ID: 15364543
[TBL] [Abstract][Full Text] [Related]
36. The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases.
Gao J; Gu Z
Front Pharmacol; 2022; 13():832732. PubMed ID: 35308207
[TBL] [Abstract][Full Text] [Related]
37. Peroxisome proliferator-activated receptors: from genes to physiology.
Kliewer SA; Xu HE; Lambert MH; Willson TM
Recent Prog Horm Res; 2001; 56():239-63. PubMed ID: 11237216
[TBL] [Abstract][Full Text] [Related]
38. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
39. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
40. [Peroxisome proliferator activated receptors PPARs: their role in carbohydrate and lipid metabolism].
Andrééva-Gatéva P
Ann Biol Clin (Paris); 2003; 61(3):295-303. PubMed ID: 12805006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
